Pharmacological opportunities to control inflammatory diseases through inhibition of the leukocyte recruitment

Pharmacological Research

Volumn 112, Issue , 2016, Pages 37-48

  Peres, Raphael S ^a   Menezes, Gustavo B ^b   Teixeira, Mauro M ^b   Cunha, Fernando Q ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Chronic inflammatory diseases; Drug discovery; Inflammation; Leukocyte recruitment; Therapies

Indexed keywords

3 [3 BROMO 4 (2,4 DIFLUOROBENZYLOXY) 6 METHYL 2 OXO 1(2H) PYRIDINYL] N,4 DIMETHYLBENZAMIDE; 4 [3 [4 (3,4 DICHLOROBENZYL) 2 MORPHOLINYLMETHYL]UREIDOMETHYL]BENZAMIDE; AMG 487; ANTIINFLAMMATORY AGENT; ARRY 502; BIMOSIAMOSE; CCX 168; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; DANIRIXIN; DF 2162; EFALIZUMAB; FIRATEGRAST; INTEGRIN; IVL 745; MARAVIROC; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; MOGAMULIZUMAB; NATALIZUMAB; NAVARIXIN; NNC 0215 0384; OC 000459; P SELECTIN GLYCOPROTEIN LIGAND 1; PENTRAXIN 3; REPARIXIN; RIVIPANSEL; SELECTIN; UNCLASSIFIED DRUG; VERCIRNON;

ALLERGIC RHINITIS; ANCA ASSOCIATED VASCULITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROHN DISEASE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; EXTRACELLULAR MATRIX; HEART MUSCLE ISCHEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; LEUKEMIA; LEUKOCYTE FUNCTION; LEUKOCYTE MIGRATION INHIBITION; LEUKOCYTE RECRUITMENT; MULTIPLE SCLEROSIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERITONITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; VASOOCCLUSIVE CRISIS; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; DRUG DEVELOPMENT; DRUG EFFECTS; LEUKOCYTE; LEUKOCYTE ROLLING; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; CHEMOTAXIS, LEUKOCYTE; CHRONIC DISEASE; DRUG DISCOVERY; HUMANS; INFLAMMATION; LEUKOCYTE ROLLING; LEUKOCYTES; MOLECULAR TARGETED THERAPY; RECEPTORS, CHEMOKINE; SELECTINS; SIGNAL TRANSDUCTION;

EID: 84956893179     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.01.015     Document Type: Review

References (157)

1. [1] Kelly, M., Hwang, J.M., Kubes, P., Modulating leukocyte recruitment in inflammation. J. Allergy Clin. Immunol. 120 (2007), 3–10.
2. [2] Kubes, P., The complexities of leukocyte recruitment. Semin. Immunol. 14 (2002), 65–72.
3. [3] Kubes, P., Payne, D., Woodman, R.C., Molecular mechanisms of leukocyte recruitment in postischemic liver microcirculation. Am. J. Physiol. Gastrointest. Liver Physiol. 283 (2002), G139–147.
4. [4] Kubes, P., Ward, P.A., Leukocyte recruitment and the acute inflammatory response. Brain Pathol. 10 (2000), 127–135.
5. [5] Lee, W.Y., Kubes, P., Leukocyte adhesion in the liver: distinct adhesion paradigm from other organs. J. Hepatol. 48 (2008), 504–512.
6. [6] Rock, K.L., Latz, E., Ontiveros, F., Kono, H., The sterile inflammatory response. Annu. Rev. Immunol. 28 (2010), 321–342.
7. [7] Ley, K., Kansas, G.S., Selectins in t-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat. Rev. Immunol. 4 (2004), 325–335.
8. [8] Galkina, E., Ley, K., Vascular adhesion molecules in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 2292–2301.
9. [9] Huo, Y., Ley, K., Adhesion molecules and atherogenesis. Acta Physiol. Scand. 173 (2001), 35–43.
10. [10] Ley, K., Burns, C., Adhesion molecules in lymphocyte trafficking and colitis. Gastroenterology 121 (2001), 1008–1010.
11. [11] Bevilacqua, M.P., Nelson, R.M., Endothelial-leukocyte adhesion molecules in inflammation and metastasis. Thromb. Haemost. 70 (1993), 152–154.
12. [12] Bevilacqua, M.P., Endothelial-leukocyte adhesion molecules. Annu. Rev. Immunol. 11 (1993), 767–804.
13. [13] Menezes, G.B., Lee, W.Y., Zhou, H., Waterhouse, C.C., Cara, D.C., Kubes, P., Selective down-regulation of neutrophil mac-1 in endotoxemic hepatic microcirculation via il-10. J. Immunol. 183 (2009), 7557–7568.
14. [14] Vanheule, V., Janssens, R., Boff, D., Kitic, N., Berghmans, N., Ronsse, I., Kungl, A.J., Amaral, F.A., Teixeira, M.M., Van Damme, J., Proost, P., Mortier, A., The positively charged cooh-terminal glycosaminoglycan-binding cxcl9(74-103) peptide inhibits cxcl8-induced neutrophil extravasation and monosodium urate crystal-induced gout in mice. J. Biol. Chem. 290 (2015), 21292–21304.
15. [15] Falsone, A., Wabitsch, V., Geretti, E., Potzinger, H., Gerlza, T., Robinson, J., Adage, T., Teixeira, M.M., Kungl, A.J., Designing cxcl8-based decoy proteins with strong anti-inflammatory activity in vivo. Biosci. Rep. 33 (2013), 743–754.
16. [16] Massena, S., Christoffersson, G., Hjertstrom, E., Zcharia, E., Vlodavsky, I., Ausmees, N., Rolny, C., Li, J.P., Phillipson, M., A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood 116 (2010), 1924–1931.
17. [17] Weninger, W., Biro, M., Jain, R., Leukocyte migration in the interstitial space of non-lymphoid organs. Nat. Rev. Immunol. 14 (2014), 232–246.
18. [18] Phillipson, M., Heit, B., Parsons, S.A., Petri, B., Mullaly, S.C., Colarusso, P., Gower, R.M., Neely, G., Simon, S.I., Kubes, P., Vav1 is essential for mechanotactic crawling and migration of neutrophils out of the inflamed microvasculature. J. Immunol. 182 (2009), 6870–6878.
19. [19] Phillipson, M., Heit, B., Colarusso, P., Liu, L., Ballantyne, C.M., Kubes, P., Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J. Exp. Med. 203 (2006), 2569–2575.
20. [20] Harding, M.G., Zhang, K., Conly, J., Kubes, P., Neutrophil crawling in capillaries; a novel immune response to staphylococcus aureus. PLoS Pathog., 10, 2014, e1004379.
21. [21] Muller, W.A., Getting leukocytes to the site of inflammation. Vet. Pathol. 50 (2013), 7–22.
22. [22] Petri, B., Phillipson, M., Kubes, P., The physiology of leukocyte recruitment: an in vivo perspective. J. Immunol. 180 (2008), 6439–6446.
23. [23] Petri, B., Kaur, J., Long, E.M., Li, H., Parsons, S.A., Butz, S., Phillipson, M., Vestweber, D., Patel, K.D., Robbins, S.M., Kubes, P., Endothelial lsp1 is involved in endothelial dome formation, minimizing vascular permeability changes during neutrophil transmigration in vivo. Blood 117 (2011), 942–952.
24. [24] Khokha, R., Murthy, A., Weiss, A., Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat. Rev. Immunol. 13 (2013), 649–665.
25. [25] Marco, M., Fortin, C., Fulop, T., Membrane-type matrix metalloproteinases: key mediators of leukocyte function. J. Leukoc. Biol. 94 (2013), 237–246.
26. [26] Singbartl, K., Green, S.A., Ley, K., Blocking p-selectin protects from ischemia/reperfusion-induced acute renal failure. FASEB J. 14 (2000), 48–54.
27. [27] Cayatte, A.J., Rupin, A., Oliver-Krasinski, J., Maitland, K., Sansilvestri-Morel, P., Boussard, M.F., Wierzbicki, M., Verbeuren, T.J., Cohen, R.A., S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler. Thromb. Vasc. Biol. 21 (2001), 1577–1584.
28. [28] Friedrich, M., Bock, D., Philipp, S., Ludwig, N., Sabat, R., Wolk, K., Schroeter-Maas, S., Aydt, E., Kang, S., Dam, T.N., Zahlten, R., Sterry, W., Wolff, G., Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch. Dermatol. Res. 297 (2006), 345–351.
29. [29] Rosen, S.D., Tsay, D., Singer, M.S., Hemmerich, S., Abraham, W.M., Therapeutic targeting of endothelial ligands for l-selectin (pnad) in a sheep model of asthma. Am. J. Pathol. 166 (2005), 935–944.
30. [30] Langer, R., Wang, M., Stepkowski, S.M., Hancock, W.W., Han, R., Li, P., Feng, L., Kirken, R.A., Berens, K.L., Dupre, B., Podder, H., Dixon, R.A., Kahan, B.D., Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines. J. Am. Soc. Nephrol. 15 (2004), 2893–2901.
31. [31] Watz, H., Bock, D., Meyer, M., Schierhorn, K., Vollhardt, K., Woischwill, C., Pedersen, F., Kirsten, A., Beeh, K.M., Meyer-Sabellek, W., Magnussen, H., Beier, J., Inhaled pan-selectin antagonist bimosiamose attenuates airway inflammation in copd. Pulm. Pharmacol. Ther. 26 (2013), 265–270.
32. [32] McEver, R.P., Rolling back neutrophil adhesion. Nat. Immunol. 11 (2010), 282–284.
33. [33] Deban, L., Russo, R.C., Sironi, M., Moalli, F., Scanziani, M., Zambelli, V., Cuccovillo, I., Bastone, A., Gobbi, M., Valentino, S., Doni, A., Garlanda, C., Danese, S., Salvatori, G., Sassano, M., Evangelista, V., Rossi, B., Zenaro, E., Constantin, G., Laudanna, C., Bottazzi, B., Mantovani, A., Regulation of leukocyte recruitment by the long pentraxin ptx3. Nat. Immunol. 11 (2010), 328–334.
34. [34] Salio, M., Chimenti, S., De Angelis, N., Molla, F., Maina, V., Nebuloni, M., Pasqualini, F., Latini, R., Garlanda, C., Mantovani, A., Cardioprotective function of the long pentraxin ptx3 in acute myocardial infarction. Circulation 117 (2008), 1055–1064.
35. [35] Fu, W., Zhang, Y., Zhang, J., Chen, W.F., Cloning and characterization of mouse homolog of the cxc chemokine receptor cxcr1. Cytokine 31 (2005), 9–17.
36. [36] Traves, S.L., Smith, S.J., Barnes, P.J., Donnelly, L.E., Specific cxc but not cc chemokines cause elevated monocyte migration in copd: a role for cxcr2. J. Leukoc. Biol. 76 (2004), 441–450.
37. [37] Bertini, R., Allegretti, M., Bizzarri, C., Moriconi, A., Locati, M., Zampella, G., Cervellera, M.N., Di Cioccio, V., Cesta, M.C., Galliera, E., Martinez, F.O., Di Bitondo, R., Troiani, G., Sabbatini, V., D'Anniballe, G., Anacardio, R., Cutrin, J.C., Cavalieri, B., Mainiero, F., Strippoli, R., Villa, P., Di Girolamo, M., Martin, F., Gentile, M., Santoni, A., Corda, D., Poli, G., Mantovani, A., Ghezzi, P., Colotta, F., Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors cxcr1 and cxcr2: prevention of reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 11791–11796.
38. [38] Cugini, D., Azzollini, N., Gagliardini, E., Cassis, P., Bertini, R., Colotta, F., Noris, M., Remuzzi, G., Benigni, A., Inhibition of the chemokine receptor cxcr2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int. 67 (2005), 1753–1761.
39. [39] Garau, A., Bertini, R., Colotta, F., Casilli, F., Bigini, P., Cagnotto, A., Mennini, T., Ghezzi, P., Villa, P., Neuroprotection with the cxcl8 inhibitor repertaxin in transient brain ischemia. Cytokine 30 (2005), 125–131.
40. [40] Coelho, A.L., Schaller, M.A., Benjamim, C.F., Orlofsky, A.Z., Hogaboam, C.M., Kunkel, S.L., The chemokine ccl6 promotes innate immunity via immune cell activation and recruitment. J. Immunol. 179 (2007), 5474–5482.
41. [41] Cunha, T.M., Barsante, M.M., Guerrero, A.T., Verri, W.A. Jr., Ferreira, S.H., Coelho, F.M., Bertini, R., Di Giacinto, C., Allegretti, M., Cunha, F.Q., Teixeira, M.M., Treatment with df 2162, a non-competitive allosteric inhibitor of cxcr1/2, diminishes neutrophil influx and inflammatory hypernociception in mice. Br. J. Pharmacol. 154 (2008), 460–470.
42. [42] Jacobs, J.P., Ortiz-Lopez, A., Campbell, J.J., Gerard, C.J., Mathis, D., Benoist, C., Deficiency of cxcr2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model. Arthritis Rheum. 62 (2010), 1921–1932.
43. [43] Kerstetter, A.E., Padovani-Claudio, D.A., Bai, L., Miller, R.H., Inhibition of cxcr2 signaling promotes recovery in models of multiple sclerosis. Exp. Neurol. 220 (2009), 44–56.
44. [44] Sumida, H., Yanagida, K., Kita, Y., Abe, J., Matsushima, K., Nakamura, M., Ishii, S., Sato, S., Shimizu, T., Interplay between cxcr2 and blt1 facilitates neutrophil infiltration and resultant keratinocyte activation in a murine model of imiquimod-induced psoriasis. J. Immunol. 192 (2014), 4361–4369.
45. [45] Leaker, B.R., Barnes, P.J., O'Connor, B., Inhibition of lps-induced airway neutrophilic inflammation in healthy volunteers with an oral cxcr2 antagonist. Respir. Res., 14, 2013, 137.
46. [46] Rennard, S.I., Dale, D.C., Donohue, J.F., Kanniess, F., Magnussen, H., Sutherland, E.R., Watz, H., Lu, S., Stryszak, P., Rosenberg, E., Staudinger, H., Cxcr2 antagonist mk-7123: a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 191 (2015), 1001–1011.
47. [47] Willerson, J.T., Pharmacologic approaches to reperfusion injury. Adv. Pharmacol. 39 (1997), 291–312.
48. [48] Souza, D.G., Bertini, R., Vieira, A.T., Cunha, F.Q., Poole, S., Allegretti, M., Colotta, F., Teixeira, M.M., Repertaxin, a novel inhibitor of rat cxcr2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br. J. Pharmacol. 143 (2004), 132–142.
49. [49] Charo, I.F., Myers, S.J., Herman, A., Franci, C., Connolly, A.J., Coughlin, S.R., Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 2752–2756.
50. [50] Szekanecz, Z., Szucs, G., Szanto, S., Koch, A.E., Chemokines in rheumatic diseases. Curr. Drug Targets 7 (2006), 91–102.
51. [51] Charo, I.F., Ransohoff, R.M., The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006), 610–621.
52. [52] Fang, W.B., Jokar, I., Zou, A., Lambert, D., Dendukuri, P., Cheng, N., Ccl2/ccr2 chemokine signaling coordinates survival and motility of breast cancer cells through smad3 protein- and p42/44 mitogen-activated protein kinase (mapk)-dependent mechanisms. J. Biol. Chem. 287 (2012), 36593–36608.
53. [53] Boring, L., Gosling, J., Cleary, M., Charo, I.F., Decreased lesion formation in ccr2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998), 894–897.
54. [54] Talbot, J., Bianchini, F.J., Nascimento, D.C., Oliveira, R.D., Souto, F.O., Pinto, L.G., Peres, R.S., Silva, J.R., Almeida, S.C., Louzada-Junior, P., Cunha, T.M., Cunha, F.Q., Alves-Filho, J.C., Ccr2 expression in neutrophils plays a critical role in their migration into the joints in rheumatoid arthritis. Arthritis Rheumatol. 67 (2015), 1751–1759.
55. [55] Ogata, H., Takeya, M., Yoshimura, T., Takagi, K., Takahashi, K., The role of monocyte chemoattractant protein-1 (mcp-1) in the pathogenesis of collagen-induced arthritis in rats. J. Pathol. 182 (1997), 106–114.
56. [56] Doring, Y., Pawig, L., Weber, C., Noels, H., The cxcl12/cxcr4 chemokine ligand/receptor axis in cardiovascular disease. Front. Physiol., 5, 2014, 212.
57. [57] Peled, A., Kollet, O., Ponomaryov, T., Petit, I., Franitza, S., Grabovsky, V., Slav, M.M., Nagler, A., Lider, O., Alon, R., Zipori, D., Lapidot, T., The chemokine sdf-1 activates the integrins lfa-1, vla-4, and vla-5 on immature human cd34(+) cells: role in transendothelial/stromal migration and engraftment of nod/scid mice. Blood 95 (2000), 3289–3296.
58. [58] Bernhagen, J., Krohn, R., Lue, H., Gregory, J.L., Zernecke, A., Koenen, R.R., Dewor, M., Georgiev, I., Schober, A., Leng, L., Kooistra, T., Fingerle-Rowson, G., Ghezzi, P., Kleemann, R., McColl, S.R., Bucala, R., Hickey, M.J., Weber, C., Mif is a noncognate ligand of cxc chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13 (2007), 587–596.
59. [59] Schiraldi, M., Raucci, A., Munoz, L.M., Livoti, E., Celona, B., Venereau, E., Apuzzo, T., De Marchis, F., Pedotti, M., Bachi, A., Thelen, M., Varani, L., Mellado, M., Proudfoot, A., Bianchi, M.E., Uguccioni, M., Hmgb1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with cxcl12 and signaling via cxcr4. J. Exp. Med. 209 (2012), 551–563.
60. [60] Lee, H., Whitfeld, P.L., Mackay, C.R., Receptors for complement c5a: the importance of c5ar and the enigmatic role of c5l2. Immunol. Cell Biol. 86 (2008), 153–160.
61. [61] Andersson, C., Wenander, C.S., Usher, P.A., Hebsgaard, J.B., Sondergaard, B.C., Rono, B., Mackay, C., Friedrichsen, B., Chang, C., Tang, R., Hornum, L., Rapid-onset clinical and mechanistic effects of anti-c5ar treatment in the mouse collagen-induced arthritis model. Clin. Exp. Immunol. 177 (2014), 219–233.
62. [62] Riedemann, N.C., Guo, R.F., Neff, T.A., Laudes, I.J., Keller, K.A., Sarma, V.J., Markiewski, M.M., Mastellos, D., Strey, C.W., Pierson, C.L., Lambris, J.D., Zetoune, F.S., Ward, P.A., Increased c5a receptor expression in sepsis. J. Clin. Investig. 110 (2002), 101–108.
63. [63] Moriconi, A., Cunha, T.M., Souza, G.R., Lopes, A.H., Cunha, F.Q., Carneiro, V.L., Pinto, L.G., Brandolini, L., Aramini, A., Bizzarri, C., Bianchini, G., Beccari, A.R., Fanton, M., Bruno, A., Costantino, G., Bertini, R., Galliera, E., Locati, M., Ferreira, S.H., Teixeira, M.M., Allegretti, M., Targeting the minor pocket of c5ar for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 16937–16942.
64. [64] Wang, Y., Rollins, S.A., Madri, J.A., Matis, L.A., Anti-c5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 8955–8959.
65. [65] Atkinson, S.M., Nansen, A., Usher, P.A., Sondergaard, B.C., Mackay, C.R., Friedrichsen, B., Chang, C.C., Tang, R., Skov, S., Haase, C., Hornum, L., Treatment with anti-c5ar mab leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model. Autoimmunity 48 (2015), 460–470.
66. [66] Griffith, J.W., Sokol, C.L., Luster, A.D., Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32 (2014), 659–702.
67. [67] Doodes, P.D., Cao, Y., Hamel, K.M., Wang, Y., Rodeghero, R.L., Kobezda, T., Finnegan, A., Ccr5 is involved in resolution of inflammation in proteoglycan-induced arthritis. Arthritis Rheum. 60 (2009), 2945–2953.
68. [68] Mohan, K., Issekutz, T.B., Blockade of chemokine receptor cxcr3 inhibits t cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis. J. Immunol. 179 (2007), 8463–8469.
69. [69] Sporici, R., Issekutz, T.B., Cxcr3 blockade inhibits t-cell migration into the cns during eae and prevents development of adoptively transferred, but not actively induced, disease. Eur. J. Immunol. 40 (2010), 2751–2761.
70. [70] Herzig, D.S., Guo, Y., Fang, G., Toliver-Kinsky, T.E., Sherwood, E.R., Therapeutic efficacy of cxcr3 blockade in an experimental model of severe sepsis. Crit. Care, 16, 2012, R168.
71. [71] Fischereder, M., Luckow, B., Hocher, B., Wuthrich, R.P., Rothenpieler, U., Schneeberger, H., Panzer, U., Stahl, R.A., Hauser, I.A., Budde, K., Neumayer, H., Kramer, B.K., Land, W., Schlondorff, D., Cc chemokine receptor 5 and renal-transplant survival. Lancet 357 (2001), 1758–1761.
72. [72] Bogunia-Kubik, K., Duda, D., Suchnicki, K., Lange, A., Ccr5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 91 (2006), 1628–1634.
73. [73] Zernecke, A., Liehn, E.A., Gao, J.L., Kuziel, W.A., Murphy, P.M., Weber, C., Deficiency in ccr5 but not ccr1 protects against neointima formation in atherosclerosis-prone mice: involvement of il-10. Blood 107 (2006), 4240–4243.
74. [74] Tacke, F., Alvarez, D., Kaplan, T.J., Jakubzick, C., Spanbroek, R., Llodra, J., Garin, A., Liu, J., Mack, M., van Rooijen, N., Lira, S.A., Habenicht, A.J., Randolph, G.J., Monocyte subsets differentially employ ccr2, ccr5, and cx3cr1 to accumulate within atherosclerotic plaques. J. Clin. Investig. 117 (2007), 185–194.
75. [75] Vierboom, M.P., Zavodny, P.J., Chou, C.C., Tagat, J.R., Pugliese-Sivo, C., Strizki, J., Steensma, R.W., McCombie, S.W., Celebi-Paul, L., Remarque, E., Jonker, M., Narula, S.K., Hart, B., Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of ccr5. Arthritis Rheum. 52 (2005), 627–636.
76. [76] Groom, J.R., Luster, A.D., Cxcr3 in t cell function. Exp. Cell Res. 317 (2011), 620–631.
77. [77] Hanaoka, R., Kasama, T., Muramatsu, M., Yajima, N., Shiozawa, F., Miwa, Y., Negishi, M., Ide, H., Miyaoka, H., Uchida, H., Adachi, M., A novel mechanism for the regulation of ifn-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res. Ther. 5 (2003), R74–81.
78. [78] Johnson, M., Li, A.R., Liu, J., Fu, Z., Zhu, L., Miao, S., Wang, X., Xu, Q., Huang, A., Marcus, A., Xu, F., Ebsworth, K., Sablan, E., Danao, J., Kumer, J., Dairaghi, D., Lawrence, C., Sullivan, T., Tonn, G., Schall, T., Collins, T., Medina, J., Discovery and optimization of a series of quinazolinone-derived antagonists of cxcr3. Bioorg. Med. Chem. Lett. 17 (2007), 3339–3343.
79. [79] Horuk, R., Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discov. 8 (2009), 23–33.
80. [80] Ondeykal, J.G., Herath, K.B., Jayasuriya, H., Polishook, J.D., Bills, G.F., Dombrowski, A.W., Mojena, M., Koch, G., DiSalvo, J., DeMartino, J., Guan, Z., Nanakorn, W., Morenberg, C.M., Balick, M.J., Stevenson, D.W., Slattery, M., Borris, R.P., Singh, S.B., Discovery of structurally diverse natural product antagonists of chemokine receptor cxcr3. Mol. Divers. 9 (2005), 123–129.
81. [81] Samson, M., Stordeur, P., Labbe, O., Soularue, P., Vassart, G., Parmentier, M., Molecular cloning and chromosomal mapping of a novel human gene, chemr1, expressed in t lymphocytes and polymorphonuclear cells and encoding a putative chemokine receptor. Eur. J. Immunol. 26 (1996), 3021–3028.
82. [82] Santiago, B., Galindo, M., Rivero, M., Brehmer, M.T., Mateo, I., Pablos, J.L., The chemoattraction of lymphocytes by rheumatoid arthritis—synovial fluid is not dependent on the chemokine receptor ccr5. Rheumatol. Int. 22 (2002), 107–111.
83. [83] Marques, R.E., Guabiraba, R., Russo, R.C., Teixeira, M.M., Targeting ccl5 in inflammation. Expert Opin. Ther. Targets 17 (2013), 1439–1460.
84. [84] Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P.D., Wu, L., Mackay, C.R., LaRosa, G., Newman, W., Gerard, N., Gerard, C., Sodroski, J., The beta-chemokine receptors ccr3 and ccr5 facilitate infection by primary hiv-1 isolates. Cell 85 (1996), 1135–1148.
85. [85] Westby, M., van der Ryst, E., Ccr5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir. Chem. Chemother. 16 (2005), 339–354.
86. [86] Bosnjak, B., Stelzmueller, B., Erb, K.J., Epstein, M.M., Treatment of allergic asthma: modulation of th2 cells and their responses. Respir. Res., 12, 2011, 114.
87. [87] Bertrand, C.P., Ponath, P.D., Ccr3 blockade as a new therapy for asthma. Expert Opin. Investig. Drugs 9 (2000), 43–52.
88. [88] Ponath, P.D., Qin, S., Ringler, D.J., Clark-Lewis, I., Wang, J., Kassam, N., Smith, H., Shi, X., Gonzalo, J.A., Newman, W., Gutierrez-Ramos, J.C., Mackay, C.R., Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J. Clin. Investig. 97 (1996), 604–612.
89. [89] Ma, W., Bryce, P.J., Humbles, A.A., Laouini, D., Yalcindag, A., Alenius, H., Friend, D.S., Oettgen, H.C., Gerard, C., Geha, R.S., Ccr3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J. Clin. Investig. 109 (2002), 621–628.
90. [90] Fulkerson, P.C., Fischetti, C.A., McBride, M.L., Hassman, L.M., Hogan, S.P., Rothenberg, M.E., A central regulatory role for eosinophils and the eotaxin/ccr3 axis in chronic experimental allergic airway inflammation. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 16418–16423.
91. [91] Neighbour, H., Boulet, L.P., Lemiere, C., Sehmi, R., Leigh, R., Sousa, A.R., Martin, J., Dallow, N., Gilbert, J., Allen, A., Hall, D., Nair, P., Safety and efficacy of an oral ccr3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin. Exp. Allergy 44 (2014), 508–516.
92. [92] Bice, J.B., Leechawengwongs, E., Montanaro, A., Biologic targeted therapy in allergic asthma. Ann. Allergy Asthma Immunol. 112 (2014), 108–115.
93. [93] Pettipher, R., Hansel, T.T., Armer, R., Antagonism of the prostaglandin d2 receptors dp1 and crth2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov. 6 (2007), 313–325.
94. [94] Acosta-Rodriguez, E.V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., Napolitani, G., Surface phenotype and antigenic specificity of human interleukin 17-producing t helper memory cells. Nat. Immunol. 8 (2007), 639–646.
95. [95] Hirota, K., Yoshitomi, H., Hashimoto, M., Maeda, S., Teradaira, S., Sugimoto, N., Yamaguchi, T., Nomura, T., Ito, H., Nakamura, T., Sakaguchi, N., Sakaguchi, S., Preferential recruitment of ccr6-expressing th17 cells to inflamed joints via ccl20 in rheumatoid arthritis and its animal model. J. Exp. Med. 204 (2007), 2803–2812.
96. [96] Liston, A., Kohler, R.E., Townley, S., Haylock-Jacobs, S., Comerford, I., Caon, A.C., Webster, J., Harrison, J.M., Swann, J., Clark-Lewis, I., Korner, H., McColl, S.R., Inhibition of ccr6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J. Immunol. 182 (2009), 3121–3130.
97. [97] Hedrick, M.N., Lonsdorf, A.S., Shirakawa, A.K., Richard Lee, C.C., Liao, F., Singh, S.P., Zhang, H.H., Grinberg, A., Love, P.E., Hwang, S.T., Farber, J.M., Ccr6 is required for il-23-induced psoriasis-like inflammation in mice. J. Clin. Investig. 119 (2009), 2317–2329.
98. [98] Pere, H., Montier, Y., Bayry, J., Quintin-Colonna, F., Merillon, N., Dransart, E., Badoual, C., Gey, A., Ravel, P., Marcheteau, E., Batteux, F., Sandoval, F., Adotevi, O., Chiu, C., Garcia, S., Tanchot, C., Lone, Y.C., Ferreira, L.C., Nelson, B.H., Hanahan, D., Fridman, W.H., Johannes, L., Tartour, E., A ccr4 antagonist combined with vaccines induces antigen-specific cd8+ t cells and tumor immunity against self antigens. Blood 118 (2011), 4853–4862.
99. [99] Comerford, I., Kara, E.E., McKenzie, D.R., McColl, S.R., Advances in understanding the pathogenesis of autoimmune disorders: focus on chemokines and lymphocyte trafficking. Br. J. Haematol. 164 (2014), 329–341.
100. [100] Forde, E.A., Dogan, R.N., Karpus, W.J., Ccr4 contributes to the pathogenesis of experimental autoimmune encephalomyelitis by regulating inflammatory macrophage function. J. Neuroimmunol. 236 (2011), 17–26.
101. [101] Shah, K., Lee, W.W., Lee, S.H., Kim, S.H., Kang, S.W., Craft, J., Kang, I., Dysregulated balance of th17 and th1 cells in systemic lupus erythematosus. Arthritis Res. Ther., 12, 2010, R53.
102. [102] Zhang, N., Pan, H.F., Ye, D.Q., Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol. Cell. Biochem. 353 (2011), 41–46.
103. [103] Bayry, J., Tartour, E., Tough, D.F., Targeting ccr4 as an emerging strategy for cancer therapy and vaccines. Trends Pharmacol. Sci. 35 (2014), 163–165.
104. [104] Ishida, T., Utsunomiya, A., Iida, S., Inagaki, H., Takatsuka, Y., Kusumoto, S., Takeuchi, G., Shimizu, S., Ito, M., Komatsu, H., Wakita, A., Eimoto, T., Matsushima, K., Ueda, R., Clinical significance of ccr4 expression in adult t-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin. Cancer Res. 9 (2003), 3625–3634.
105. [105] Tobinai, K., Development of novel therapeutic agents for adult t-cell leukemia-lymphoma. Rinsho Ketsueki 53 (2012), 1665–1674.
106. [106] Zabel, B.A., Agace, W.W., Campbell, J.J., Heath, H.M., Parent, D., Roberts, A.I., Ebert, E.C., Kassam, N., Qin, S., Zovko, M., LaRosa, G.J., Yang, L.L., Soler, D., Butcher, E.C., Ponath, P.D., Parker, C.M., Andrew, D.P., Human g protein-coupled receptor gpr-9-6/cc chemokine receptor 9 is selectively expressed on intestinal homing t lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J. Exp. Med. 190 (1999), 1241–1256.
107. [107] Kunkel, E.J., Campbell, J.J., Haraldsen, G., Pan, J., Boisvert, J., Roberts, A.I., Ebert, E.C., Vierra, M.A., Goodman, S.B., Genovese, M.C., Wardlaw, A.J., Greenberg, H.B., Parker, C.M., Butcher, E.C., Andrew, D.P., Agace, W.W., Lymphocyte cc chemokine receptor 9 and epithelial thymus-expressed chemokine (teck) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J. Exp. Med. 192 (2000), 761–768.
108. [108] Wurbel, M.A., McIntire, M.G., Dwyer, P., Fiebiger, E., Ccl25/ccr9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PLoS One, 6, 2011, e16442.
109. [109] Svensson, M., Agace, W.W., Role of ccl25/ccr9 in immune homeostasis and disease. Expert Rev. Clin. Immunol. 2 (2006), 759–773.
110. [110] Schmutz, C., Cartwright, A., Williams, H., Haworth, O., Williams, J.H., Filer, A., Salmon, M., Buckley, C.D., Middleton, J., Monocytes/macrophages express chemokine receptor ccr9 in rheumatoid arthritis and ccl25 stimulates their differentiation. Arthritis Res. Ther., 12, 2010, R161.
111. [111] Yokoyama, W., Kohsaka, H., Kaneko, K., Walters, M., Takayasu, A., Fukuda, S., Miyabe, C., Miyabe, Y., Love, P.E., Nakamoto, N., Kanai, T., Watanabe-Imai, K., Charvat, T.T., Penfold, M.E., Jaen, J., Schall, T.J., Harigai, M., Miyasaka, N., Nanki, T., Abrogation of cc chemokine receptor 9 ameliorates collagen-induced arthritis of mice. Arthritis Res. Ther., 16, 2014, 445.
112. [112] Feagan, B.G., Sandborn, W.J., D'Haens, G., Lee, S.D., Allez, M., Fedorak, R.N., Seidler, U., Vermeire, S., Lawrance, I.C., Maroney, A.C., Jurgensen, C.H., Heath, A., Chang, D.J., Randomised clinical trial: vercirnon, an oral ccr9 antagonist, vs. placebo as induction therapy in active crohn's disease. Aliment. Pharmacol. Ther. 42 (2015), 1170–1181.
113. [113] Herter, J., Zarbock, A., Integrin regulation during leukocyte recruitment. J. Immunol. 190 (2013), 4451–4457.
114. [114] Kappos, L., Bates, D., Edan, G., Eraksoy, M., Garcia-Merino, A., Grigoriadis, N., Hartung, H.P., Havrdova, E., Hillert, J., Hohlfeld, R., Kremenchutzky, M., Lyon-Caen, O., Miller, A., Pozzilli, C., Ravnborg, M., Saida, T., Sindic, C., Vass, K., Clifford, D.B., Hauser, S., Major, E.O., O'Connor, P.W., Weiner, H.L., Clanet, M., Gold, R., Hirsch, H.H., Radu, E.W., Sorensen, P.S., King, J., Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 10 (2011), 745–758.
115. [115] Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H., Phillips, J.T., Lublin, F.D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M.A., Sandrock, A.W., Investigators, A., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006), 899–910.
116. [116] Coisne, C., Mao, W., Engelhardt, B., Cutting edge: natalizumab blocks adhesion but not initial contact of human t cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J. Immunol. 182 (2009), 5909–5913.
117. [117] Millard, M., Odde, S., Neamati, N., Integrin targeted therapeutics. Theranostics 1 (2011), 154–188.
118. [118] Norris, V., Choong, L., Tran, D., Corden, Z., Boyce, M., Arshad, H., Holgate, S., O'Connor, B., Millet, S., Miller, B., Rohatagi, S., Kirkesseli, S., Effect of ivl745, a vla-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. J. Allergy Clin. Immunol. 116 (2005), 761–767.
119. [119] Pietrzak, A., Podhorecka, M., Chodorowska, G., Rolinski, J., Urban, J., Efaluzimab in the treatment of psoriasis. Ann. Univ. Mariae Curie Sklodowska Med. 58 (2003), 174–178.
120. [120] Gordon, K.B., Papp, K.A., Hamilton, T.K., Walicke, P.A., Dummer, W., Li, N., Bresnahan, B.W., Menter, A., Efalizumab Study, G., Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290 (2003), 3073–3080.
121. [121] Lebwohl, M., Tyring, S.K., Hamilton, T.K., Toth, D., Glazer, S., Tawfik, N.H., Walicke, P., Dummer, W., Wang, X., Garovoy, M.R., Pariser, D., Efalizumab Study, G., A novel targeted t-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349 (2003), 2004–2013.
122. [122] Leonardi, C.L., Papp, K.A., Gordon, K.B., Menter, A., Feldman, S.R., Caro, I., Walicke, P.A., Compton, P.G., Gottlieb, A.B., Efalizumab Study, G., Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase iii trial. J. Am. Acad. Dermatol. 52 (2005), 425–433.
123. [123] Hidai, C., Zupancic, T., Penta, K., Mikhail, A., Kawana, M., Quertermous, E.E., Aoka, Y., Fukagawa, M., Matsui, Y., Platika, D., Auerbach, R., Hogan, B.L., Snodgrass, R., Quertermous, T., Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the alphavbeta3 integrin receptor. Genes Dev. 12 (1998), 21–33.
124. [124] Choi, E.Y., Chavakis, E., Czabanka, M.A., Langer, H.F., Fraemohs, L., Economopoulou, M., Kundu, R.K., Orlandi, A., Zheng, Y.Y., Prieto, D.A., Ballantyne, C.M., Constant, S.L., Aird, W.C., Papayannopoulou, T., Gahmberg, C.G., Udey, M.C., Vajkoczy, P., Quertermous, T., Dimmeler, S., Weber, C., Chavakis, T., Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science 322 (2008), 1101–1104.
125. [125] Choi, E.Y., Lim, J.H., Neuwirth, A., Economopoulou, M., Chatzigeorgiou, A., Chung, K.J., Bittner, S., Lee, S.H., Langer, H., Samus, M., Kim, H., Cho, G.S., Ziemssen, T., Bdeir, K., Chavakis, E., Koh, J.Y., Boon, L., Hosur, K., Bornstein, S.R., Meuth, S.G., Hajishengallis, G., Chavakis, T., Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination. Mol. Psychiatry 20 (2015), 880–888.
126. [126] Eskan, M.A., Jotwani, R., Abe, T., Chmelar, J., Lim, J.H., Liang, S., Ciero, P.A., Krauss, J.L., Li, F., Rauner, M., Hofbauer, L.C., Choi, E.Y., Chung, K.J., Hashim, A., Curtis, M.A., Chavakis, T., Hajishengallis, G., The leukocyte integrin antagonist del-1 inhibits il-17-mediated inflammatory bone loss. Nat. Immunol. 13 (2012), 465–473.
127. [127] Castor, M.G., Rezende, B.M., Bernardes, P.T., Vieira, A.T., Vieira, E.L., Arantes, R.M., Souza, D.G., Silva, T.A., Teixeira, M.M., Pinho, V., Pi3kgamma controls leukocyte recruitment, tissue injury, and lethality in a model of graft-versus-host disease in mice. J. Leukoc. Biol. 89 (2011), 955–964.
128. [128] Vanhaesebroeck, B., Vogt, P.K., Rommel, C., Pi3k: from the bench to the clinic and back. Curr. Top. Microbiol. Immunol. 347 (2010), 1–19.
129. [129] Berod, L., Heinemann, C., Heink, S., Escher, A., Stadelmann, C., Drube, S., Wetzker, R., Norgauer, J., Kamradt, T., Pi3kgamma deficiency delays the onset of experimental autoimmune encephalomyelitis and ameliorates its clinical outcome. Eur. J. Immunol. 41 (2011), 833–844.
130. [130] Camps, M., Ruckle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Francon, B., Martin, T., Gretener, D., Perrin, D., Leroy, D., Vitte, P.A., Hirsch, E., Wymann, M.P., Cirillo, R., Schwarz, M.K., Rommel, C., Blockade of pi3kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11 (2005), 936–943.
131. [131] Rodon, J., Dienstmann, R., Serra, V., Tabernero, J., Development of pi3k inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10 (2013), 143–153.
132. [132] Thorpe, L.M., Yuzugullu, H., Zhao, J.J., Pi3k in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15 (2015), 7–24.
133. [133] Randis, T.M., Puri, K.D., Zhou, H., Diacovo, T.G., Role of pi3kdelta and pi3kgamma in inflammatory arthritis and tissue localization of neutrophils. Eur. J. Immunol. 38 (2008), 1215–1224.
134. [134] Maira, S.M., Stauffer, F., Schnell, C., Garcia-Echeverria, C., Pi3k inhibitors for cancer treatment: where do we stand?. Biochem. Soc. Trans. 37 (2009), 265–272.
135. [135] Cuenda, A., Rousseau, S., P38 map-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 1773 (2007), 1358–1375.
136. [136] Smolen, J.E., Petersen, T.K., Koch, C., O'Keefe, S.J., Hanlon, W.A., Seo, S., Pearson, D., Fossett, M.C., Simon, S.I., L-selectin signaling of neutrophil adhesion and degranulation involves p38 mitogen-activated protein kinase. J. Biol. Chem. 275 (2000), 15876–15884.
137. [137] Nahas, N., Molski, T.F., Fernandez, G.A., Sha'afi, R.I., Tyrosine phosphorylation and activation of a new mitogen-activated protein (map)-kinase cascade in human neutrophils stimulated with various agonists. Biochem. J. 318:Pt 1 (1996), 247–253.
138. [138] Nick, J.A., Avdi, N.J., Gerwins, P., Johnson, G.L., Worthen, G.S., Activation of a p38 mitogen-activated protein kinase in human neutrophils by lipopolysaccharide. J. Immunol. 156 (1996), 4867–4875.
139. [139] Zu, Y.L., Qi, J., Gilchrist, A., Fernandez, G.A., Vazquez-Abad, D., Kreutzer, D.L., Huang, C.K., Sha'afi, R.I., P38 mitogen-activated protein kinase activation is required for human neutrophil function triggered by tnf-alpha or fmlp stimulation. J. Immunol. 160 (1998), 1982–1989.
140. [140] Haddad, E.B., Birrell, M., McCluskie, K., Ling, A., Webber, S.E., Foster, M.L., Belvisi, M.G., Role of p38 map kinase in lps-induced airway inflammation in the rat. Br. J. Pharmacol. 132 (2001), 1715–1724.
141. [141] Lea, S., Harbron, C., Khan, N., Booth, G., Armstrong, J., Singh, D., Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (mapk) inhibitor. Br. J. Clin. Pharmacol. 79 (2015), 756–766.
142. [142] Hollenbach, E., Neumann, M., Vieth, M., Roessner, A., Malfertheiner, P., Naumann, M., Inhibition of p38 map kinase- and rick/nf-kappab-signaling suppresses inflammatory bowel disease. FASEB J. 18 (2004), 1550–1552.
143. [143] Guma, M., Hammaker, D., Topolewski, K., Corr, M., Boyle, D.L., Karin, M., Firestein, G.S., Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases mkk-3 or mkk-6. Arthritis Rheum. 64 (2012), 2887–2895.
144. [144] Page, T.H., Brown, A., Timms, E.M., Foxwell, B.M., Ray, K.P., Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: does variable inhibition of interleukin-6 production limit effectiveness in vivo. Arthritis Rheum. 62 (2010), 3221–3231.
145. [145] Campbell, J., Ciesielski, C.J., Hunt, A.E., Horwood, N.J., Beech, J.T., Hayes, L.A., Denys, A., Feldmann, M., Brennan, F.M., Foxwell, B.M., A novel mechanism for tnf-alpha regulation by p38 mapk: involvement of nf-kappa b with implications for therapy in rheumatoid arthritis. J. Immunol. 173 (2004), 6928–6937.
146. [146] Jin, N., Wang, Q., Zhang, X., Jiang, D., Cheng, H., Zhu, K., The selective p38 mitogen-activated protein kinase inhibitor, sb203580, improves renal disease in mrl/lpr mouse model of systemic lupus. Int. Immunopharmacol. 11 (2011), 1319–1326.
147. [147] Lee, J.C., Kumar, S., Griswold, D.E., Underwood, D.C., Votta, B.J., Adams, J.L., Inhibition of p38 map kinase as a therapeutic strategy. Immunopharmacology 47 (2000), 185–201.
148. [148] Lam, P.Y., Yoo, S.K., Green, J.M., Huttenlocher, A., The sh2-domain-containing inositol 5-phosphatase (ship) limits the motility of neutrophils and their recruitment to wounds in zebrafish. J. Cell Sci. 125 (2012), 4973–4978.
149. [149] Spertini, C., Baisse, B., Spertini, O., Ezrin-radixin-moesin-binding sequence of psgl-1 glycoprotein regulates leukocyte rolling on selectins and activation of extracellular signal-regulated kinases. J. Biol. Chem. 287 (2012), 10693–10702.
150. [150] Edelman, M.J., Burrows, W., Krasna, M.J., Bedor, M., Smith, R., Suntharalingam, M., Phase i trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in stage iii non-small cell lung cancer. Lung Cancer 68 (2010), 84–88.
151. [151] Dambach, D.M., Potential adverse effects associated with inhibition of p38alpha/beta map kinases. Curr. Top. Med. Chem. 5 (2005), 929–939.
152. [152] Foukas, L.C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A.J., Withers, D.J., Vanhaesebroeck, B., Critical role for the p110alpha phosphoinositide-3-oh kinase in growth and metabolic regulation. Nature 441 (2006), 366–370.
153. [153] Busaidy, N.L., Farooki, A., Dowlati, A., Perentesis, J.P., Dancey, J.E., Doyle, L.A., Brell, J.M., Siu, L.L., Management of metabolic effects associated with anticancer agents targeting the pi3k-akt-mtor pathway. J. Clin. Oncol. 30 (2012), 2919–2928.
154. [154] Mackay, C.R., Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat. Immunol. 9 (2008), 988–998.
155. [155] Russo, R.C., Garcia, C.C., Teixeira, M.M., Anti-inflammatory drug development: broad or specific chemokine receptor antagonists. Curr. Opin. Drug Discov. Dev. 13 (2010), 414–427.
156. [156] Alessandri, A.L., Sousa, L.P., Lucas, C.D., Rossi, A.G., Pinho, V., Teixeira, M.M., Resolution of inflammation: mechanisms and opportunity for drug development. Pharmacol. Ther. 139 (2013), 189–212.
157. [157] Sousa, L.P., Alessandri, A.L., Pinho, V., Teixeira, M.M., Pharmacological strategies to resolve acute inflammation. Curr. Opin. Pharmacol. 13 (2013), 625–631.